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ABSTRAK
Latar belakang: pasien striktur bilier distal maligna unresectable memerlukan pemasangan stent bilier per 
endoskopik. Tingkat kesintasan dan faktor-faktor yang memengaruhinya di Indonesia belum diketahui. Tujuan 
penelitian ini untuk mengetahui kesintasan 6 bulan pasien striktur bilier distal maligna pasca pemasangan stent 
bilier per endoskopik dan faktor-faktor yang berpengaruh. Metode: penelitian dengan desain kohort retrospektif 
menggunakan rekam medik pasien striktur bilier distal maligna unresectable, yang meliputi kanker kaput pankreas, 
ampulla/ papilla Vateri, atau kolangiokarsinoma distal pasca stent bilier per endoskopik, dilakukan  di RSUPN-CM 
pada Juni 2015–Agustus 2017. Kesintasan kumulatif dinyatakan dengan Kurva Kaplan-Meier. Analisis bivariat 
dan multivariat dilakukan menggunakan regresi Cox terhadap beberapa faktor yaitu kegagalan pemasangan 
stent, adanya perdarahan, sepsis, komorbid, malnutrisi, dan kadar albumin serum. Hasil: dari total 120 subjek, 85 
subjek meninggal 6 bulan pasca stent, dengan proporsi kesintasan 180 hari sebesar 24%, dan median kesintasan 
81 hari (IK95% 56–106 hari). Faktor komorbid, sepsis, malnutrisi, dan albumin ≤ 3,0 g/dL memiliki nilai p<0,25 
pada analisis bivariat; sedangkan analisis multivariat berikutnya menunjukkan bahwa kadar albumin ≤ 3,0 g/dL 
memiliki HR 2,73 (IK95% 1,48–5,05; p=0,001). Kesimpulan: kesintasan 6 bulan pasca stent bilier per endoskopik 
adalah 24% dengan median kesintasan 81 hari. Kadar albumin ≤ 3,0 g/dL memiliki risiko 2,73 kali lebih besar 
untuk mortalitas 6 bulan.
Kata kunci: kesintasan, striktur bilier distal maligna, stent bilier per endoskopik, faktor terkait mortalitas, 
albumin.
ABSTRACT
Background: unresectable malignant distal biliary stricture patients require  endoscopic biliary stent placement 
procedure. The survival rate and its associated factors in Indonesia are unknown. This study aimed to identify 
6-month survival of patients with malignant distal biliary stricture following endoscopic biliary stent procedure 
and its associated factors. Methods: a retrospective cohort study was conducted using medical records of patients 
with unresectable malignant distal biliary stricture, which involved caput of pancreas, ampulla of Vater or distal 
cholangiocarcinoma following endoscopic biliary stent procedure between June 2015 and August 2017 at Cipto 
Mangunkusumo National Central General Hospital. The cumulative survival was defined by using the Kaplan-
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Meier curve. Bivariate and multivariate analyses were performed using Cox regression of some factors including 
failure of biliary stent insertion, bleeding, sepsis, comorbidities, malnutrition, and serum albumin levels. Results: 
out of total 120 subjects, 85 subjects died within 6 months following the stent procedure with a proportion of 180-
day survival of 24% and a median survival of 81 days (CI 95%: 56–106 days). In bivariate analysis, factors of 
comorbidities, sepsis, malnutrition and albumin levels ≤ 3.0 g/dL had p values of < 0.25; while the subsequent 
multivariate analysis showed that albumin level of ≤ 3.0 g/dL had HR of 2.73 (CI 95%: 1.48 – 5.05; p = 0.001). 
Conclusion: the 6-month survival following endoscopic biliary stent procedure is 24% with a median survival of 
81 days. Albumin level of ≤ 3.0 g/dL has a 2.73 times greater risk for 6-month mortality rate.
Keywords: survival, malignant distal biliary stricture, endoscopic biliary stenting, mortality-related factors, 
albumin.
INTRODUCTION
Distal biliary stricture with clinical 
manifestation of obstructive jaundice can be 
caused by pancreatobiliary malignancies and the 
cases are increasing from 48% 1 into 53% 2 at 
Cipto Mangunkusumo National Central General 
Hospital compared to previous data a decade 
ago. The pancreatobiliary malignancies may 
be primary, such as malignancies of the head 
of the pancreas (caput of pancreas), ampulla 
of Vater, distal cholangiocarcinoma, or it may 
be secondary due to metastatic lesions, for 
instance.1,2 Often, the patients are diagnosed with 
advanced stages, including both unresectable or 
unoperable patients; therefore, the mortality rate 
is high. In developing countries, the mortality 
rate due to pancreatobiliary malignancies ranks 
fifth following lung, colorectal, breast and 
prostate cancers.3 The 5-year survival rate of 
pancreatobiliary malignancy cases is only 5% 
or less, with a global median of 3- to 6-month 
survival, and it is 4.1% in Shanghai with a median 
survival time of 3.9 months.4
Palliative care for biliary drainage may 
include performing endoscopic biliary stent 
procedure (ERCP/ EUS-BD).5,6 Although the 
procedure is known as the first-line treatment 
in addition to percutaneous drainage or biliary 
bypass surgery, but it also has some risks 
for complications, which are associated with 
mortality.2,6 Kurniawan et al found that the 
3-month mortality rate for malignant obstructive 
jaundice cases is 55.2% with overall median 
survival time of 26 days.2 However, data on 
survival of patients with distal biliary stricture 
due to unresectable malignancy, particularly 
following palliative care of endoscopic biliary 
stent procedure has not been available in 
Indonesia.
The aim of our study was to identify 6-month 
survival rate of patients with malignant distal 
biliary stricture following endoscopic biliary stent 
procedure at PESC Unit of Cipto Mangunkusumo 
National Central General Hospital in Jakarta, 
as well as its associated factors. We assumed 
that some factors may affect the survival rate 
including comorbidities,2,7 malnutrition,7,8 low 
albumin level,9-11 bleeding,12,13 failure at biliary 
stent placement,2,13 and sepsis.2,7,8,14
METHODS
Our study was a retrospective cohort on adult 
patients (age >18 years), who had unresectable 
malignant distal biliary stricture case and 
underwent endoscopic biliary stent procedure 
at the Gastrointestinal Endoscopy Center/ Pusat 
Endoskopi Saluran Cerna (PESC), Department 
of Internal Medicine, Cipto Mangunkusumo 
Hospital between June 2015 and August 2017.
Data was retrieved using total sampling 
technique by tracing medical records and 
electronic health record of the patients 
consecutively until the minimal limit of sample 
size was fulfilled, which was 120 subjects. The 
present study had been approved by Medical 
Ethic Committee – Faculty of Medicine, 
University of Indonesia with ethic number of 
0298/UN2.F1/ETIK/2018.
The collected data included subject 
characteristics, which were age, sex, type 
of malignancies based on diagnostic work-
up (histopathology, radiology imaging and 
Vol 52 • Number 1 • January 2020                 Six-month survival of patients with malignant distal biliary stricture
33
ERCP), history of other diseases for evaluation 
of comorbidities, sepsis, bleeding, status of 
successful biliary stent placement and the types, 
the current albumin level and nutritional status 
when the procedure was performed including 
malnutrition screening tools (MST) score and 
the current body mass index (BMI).
The presence of comorbidities in the subjects 
was identified based on the total score of Charlson 
comorbidity index of ≥ 4 as documented on their 
medical records. Malnutrition was defined as 
unintentional weight loss or reduced dietary 
intake with MST score of ≥ 2, and/or the 
patient was categorized as underweight, i.e. 
BMI <18.5 kg/m2. The presence or absence of 
sepsis was categorized based on diagnosis made 
on the subjects’ medical records at their last 
hospitalization following biliary stent placement 
procedure, which was consistent with qSOFA 
score criteria of ≥ 2 with an evidence of infection. 
 Hypoalbuminemia was defined as low serum 
albumin levels in subjects who had been examined 
on their last hospitalization for having endoscopic 
biliary stent procedure. The albumin level was 
categorized low when it was ≤ 3.0 g/dL. Bleeding 
was defined when there is a clinical evidence of 
gastrointestinal bleeding or with difference of 
Hb level of ≥ 2 gr/dL between before and after 
procedure. Failure of biliary stent placement 
was defined by unsuccessful cannulation and/or 
biliary stent placement during ERCP or EUS-BD 
procedure by a competent operator.
We evaluated outcomes of mortality and the 
time of death of the observed subjects (time to 
event), which were determined since the first 
placement of endoscopic biliary stent. When 
the subjects was untrackable (lost to follow up) 
on last observation after the procedure had been 
performed, the subject was considered as alive 
on the recorded date in last outpatient medical 
records and was censored in the survival analysis.
Data analysis was performed using statistic 
program of SPSS version 23.0 for univariate, 
bivariate and multivariate analyses. The level 
of significance used in our study was α = 0.05. 
Variables were considered significant when the p 
value < 0.05. Survival analysis using the Kaplan-
Meier curve was performed, which was followed 
by Cox proportional hazard regression. The 
variables were then included into a multivariate 
model when the p value < 0.25.
RESULTS
Within the period of the study, we found 
144 adult patients aged >18 years who fulfilled 
inclusion criteria. As many as 24 subjects were 
excluded due to incomplete data in their medical 
records; therefore, we found 120 subjects with 
characteristics as shown in Table 1.
Table 1. Subject’s characteristics
Characteristics n (%)
Age
 - < 60 years 73 (60.8)
 - ≥ 60 years 47 (39.2)
Sex
 - Male 56 (46.7)
 - Female 64 (53.3)
Histopathology
 - Carcinoma of caput 
pancreas 34 (28.3)
 - Papilla vater/ periampullar 
carcinoma 34 (28.3)
 - Distal cholangiocarcinoma 23 (19.2)
 - Inconclusive/ other lession 29 (24.2)
Stent
 - Successful 111 (92.5)
 - Plastic stent 80 (72.1)
 - Metal stent 31 (27.9)
 - Failed 9 (7.5)
Sepsis
 - Yes 28 (23.3)
 - No 92 (76.7)
Bleeding
 - Yes 20 (16.7)
 - No 100 (83.3)
Comorbidities
 - Present 59 (49.2)
 - Absent 61 (50.8)
Malnutrition
 - Yes 79 (65.8)
 - No 41 (34.2)
Albumin
 - > 3.0 g/dL 28 (23.3)
 - ≤ 3.0 g/dL 92 (76.7)
Outcome 6 months 1 year
 - Alive 35 (29.2) 22 (18,3)
 - Dead 85 (70.8) 98 (81,7)
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The proportion of survival in patients with 
malignant distal biliary stricture following 
endoscopic biliary stent procedure based on 
observation of day 30, 60, 90, 180 and 360 was 
58%, 46%, 38%, 24% and 6%, respectively as 
can be seen in Table 2; therefore, we found that 
the proportion of 3 month and 6 month mortality 
rate following the procedure was 62% and 
76%, respectively. By the Kaplan-Meier curve 
in Figure 1, showed that median survival time 
(which was the time when 50% of study subjects 
survived) was 81 days, with a range between 
56-106 days after the biliary stent placement 
procedure had been done.
affect the survival of subjects with malignant 
distal biliary stricture following endoscopic stent 
procedure. The analysis was done using Cox 
regression analysis. The degree of association 
was presented in the form of hazard ratio 
(HR). Four variables, which were included as 
candidates in the multivariate analysis using 
Cox Proportional Hazard Model (Table 4), were 
variables with p value < 0.25 in the bivariate 
analysis, which were sepsis, the presence of 
Table 2. Proportion of survival in patients with malignant 
distal biliary stricture following endoscopic biliary stent 
procedure






Figure 1. The Kaplan-Meier curve on 6-month survival 
of patients with malignant distal biliary stricture following 
endoscopic biliary stent procedure.
Table 3. Bivariate analysis on factors affecting 6-month survival in patients with malignant distal biliary stricture following 
endoscopic biliary stent procedure.
Variables Alive, n(%) Dead, n(%) HR (95% CI ) p value
Stent
 - Failed 2 (22.2) 7 (77.8) 0.7 (0.3 – 1.6) 0.414
 - Successful 33 (29.7) 78 (70.2)
Sepsis
 - Yes 4 (14.3) 24 (85.7) 1.6 (1.0 – 2.7) 0.035
 - No 31 (33.7) 61 (66.3)
Bleeding
 - Yes 6 (30.0) 14 (70.0) 1.2 (0.7 – 2.1) 0.592
 - No 29 (29.0) 71 (71.0)
Comorbidities
 - Present 14 (23.7) 45 (76.3) 1.4 (0.9 – 2.1) 0.119
 - Absent 21 (34.4) 40 (65.6)
Malnutrition
 - Yes 18 (22.8) 61 (77.2) 1.8 (1.1 – 2.9) 0.017
 - No 17 (41.5) 24 (58.5)
Albumin
 - ≤ 3.0 g/dL 19 (20.7) 73 (79.3) 2.7 (1.5 – 5.0) 0.001
 - > 3.0 g/dL 16 (57.1) 12 (42.8)
Bivariate analysis, which is presented in 
Table 3, was performed to evaluate factors that 
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comorbidities, the presence of malnutrition 
and albumin level of ≤ 3.0 g/dL. At the end of 
multivariate analysis, we found a significant 
variable (p<0.05) that affected survival, which 
was serum albumin level of ≤3.0 g/dL.
Subjects with albumin level of 3.0 g/dL or 
less had a risk of death as great as 2.73 times 
(95% CI: 1.48 – 5.05) compared to subjects with 
albumin level > 3.0 g/dL. It was statistically 
significant with p value of 0.001. Meanwhile, 
other variables, which were comorbidities, 
malnutrition and sepsis did not affect the 
subjects’ survival.
DISCUSSION
In the present study, out of 111 subjects 
who had successful placement of biliary stent 
procedure mostly were subjects with plastic 
stent, that were 80 (72.1%) subjects and the other 
31 (27.9%) subjects had metal stent. Median 
cumulative survival of subjects between both 
groups of biliary stent type was relatively very 
different, which was 66 days (95%CI: 38 – 93 
days) for subjects with plastic stents and 160 
days (95%CI: 53 – 267 days) for subjects with 
metal stent.
The 3-month cumulative survival in a 
study conducted by Kurniawan et al.2 on 
patients with malignant obstructive jaundice 
at Cipto Mangunkusumo Hospital between 
2010 and 2014 was 27.7% with median 
survival time of 26 days (95%CI: 20.8–31.2). 
Such difference may occur since the sample 
population in Kurniawan et al study also 
included all patients with pancreatobiliary 
malignancies that caused obstructive jaundice 
along with all kinds of treatment, both surgical 
and non-surgical treatment (endoscopic or 
percutaneous); while the population in our study 
was more homogenous, i.e. only unresectable 
pancreatobiliary malignancy cases located at the 
distal part of the biliary duct were included as 
the indication for performing endoscopic biliary 
stent procedure.
Another study conducted by Saudale et al 
found that the one-year cumulative survival 
rate in patients with pancreatic cancer at Cipto 
Mangunkusumo Hospital between 2012 and 
2016 was 14% with median survival time of 6 
months, which also means that the proportion of 
6-month cumulative survival was 50% subjects.15 
Their results are different from our results that 
found the proportion of 6-month survival of 
24% with median survival time of 81 days. 
The difference may occur since in the study15 
is more specific and was only conducted in a 
population of pancreatic cancer patients with all 
kinds of care, either curative, palliative care or 
even without treatment. While in our study, we 
included all kinds of histopathological causes 
of malignant distal biliary stricture, not only 
the pancreatic cancer, but with homogenous 
treatment, i.e. only endoscopic biliary stent 
procedure as the biliary drainage.
In the bivariate analysis of our study, we 
found that subjects who experienced sepsis had 
1.6 times greater risk of death within 6 months 
following endoscopic biliary stent procedure 
Table 4. Multivariate analysis on factors affecting 6 month survival in patients with malignant distal biliary stricture following 
endoscopic biliary stent procedure
Steps Variables HR (95%CI) p value
1st Albumin ≤ 3.0 g/dL 2.22 (1.13 – 4.37 ) 0.021
Malnutrition 1.31 (0.77 – 2.22) 0.314
Comorbidities 1.28 (0.81 – 2.03) 0.292
Sepsis 1.32 (0.79 – 2.19) 0.287
2nd Albumin ≤ 3.0 g/dL 2.56 (1.38 – 4.75) 0.003
Comorbidities 1.22 (0.78 – 1.92) 0.383
Sepsis 1.36 (0.82 – 2.25) 0.232
3rd Albumin ≤ 3.0 g/dL 2.58 (1.39 – 4.79) 0.003
Sepsis 1.46 (0.91 – 2.36) 0.116
4th Albumin ≤ 3.0 g/dL 2.73 (1.48 – 5.05) 0.001
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(95% CI: 1.0 – 2.7) and it was statistically 
significant on survival (p=0.035). However, 
when it was followed with multivariate analysis, 
sepsis became not significant (p=0.116). The 
results are different from those in Chalya et al 
study in 2006 to 2010 that found sepsis as one 
of predictor factors for mortality in patients 
with obstructive jaundice (p<0.001).14 Similar to 
that, a study by Moghimi et al also support the 
results that sepsis is one of main predictors for 
mortality rate in hospitalized patients with odds 
ratio of 7.123 (95%CI: 4.78–13.54; p<0.001).8 
Another study by Kurniawan et al found sepsis 
as an independent prognostic factor with HR of 
2.46 (95%CI: 1.55–3.91; p<0.001) in addition to 
other evaluated factors, i.e. hypoalbuminemia, 
non-ampulla Vater malignancies, initial bilirubin 
level of ≥15 mg/dL, unsuccessful/ no biliary 
drainage and Charlson comorbidity index score 
of 4 or more.2
Failure at endoscopic biliary placement had 
0.7 times greater risk of death within 6 months 
following the procedure (95% CI: 0.3–1.6) 
based on bivariate analysis and it did not show 
statistically significant correlation to survival 
(p=0.414); therefore, it was not followed by 
multivariate analysis. Biliary drainage in the 
malignancy cases was performed as an essential 
palliative therapy as it could alleviate clinical 
symptoms caused by hyperbilirubinemia; 
therefore, it enabled physical improvement and 
quality of life of the patient.6 With advances in 
endoscopic technique, ERCP with biliary stent 
placement becomes main choice of treatment 
for malignant distal biliary stricture cases. 
When CBD cannulation is difficult to perform 
due to the obstructing tumor mass, the biliary 
stent can be placed using EUS-BD.5,13 Our study 
did not differentiate the proportion of how the 
procedure of endoscopic biliary stent placement 
was performed, whether by ERCP or EUS-BD. 
Paik et al reported that there was no significant 
survival between ERCP vs. EUS-BD for biliary 
stent placement as primary palliative treatment 
in malignant obstructive jaundice, with overall 
median survival time in ERCP group was 178 
days compared to 144 days in the EUS-BD group 
(p=0.92).16
The presence of comorbidities, which was 
evaluated with Charlson comorbidity index 
score of ≥4, had 1.4 times greater risk of death 
within six months following endoscopic biliary 
stent procedure (95% CI 0.9–2.1) compared to 
subjects with score < 4 (p = 0.119). When it 
was continued with multivariate analysis, the 
comorbidities variable did not have a strong 
effect on 6-month survival and the power of this 
variable in our study was relatively low (31.4%). 
Nakai Y, et al.17 suggested that comorbidities 
have more roles as prognostic factors in patients 
with advanced stage of pancreatic cancer. 
Though there are differences in capacity of 
predicting mortality using the index for cancer 
with a relatively long life expectancy (such as 
breast cancer or prostate cancer) compared to 
cancer with low life expectancy (lung cancer or 
pancreatic cancer), the Charlson comorbidity 
index has been widely used in various studies that 
evaluate the correlation between comorbidities 
and mortality or with treatment success.18
Based on bivariate analysis on the bleeding 
variable, we found that subjects with bleeding 
had mortality risk within 180 days following 
endoscopic biliary stent as many as 1.2 times 
(95%CI: 0.7–2.1). However, the presence or 
absence of bleeding did not have statistically 
significant correlation with subject’s survival 
(p > 0.592); therefore, it was not continued into 
multivariate analysis (p>0.25). Bleeding with 
clinical evidence and signs of a decrease of 
hemoglobin level of more than 2 g/dL or there 
was a need for blood product transfusion were 
found as complications of ERCP procedure 
performed at Cipto Mangunkusumo National 
Central General Hospital in 3 out of 54 patients 
(5.5%).12
Although the rate of bleeding is relatively 
small, but with the presence of malignant lesion 
in biliary tract, particularly at distal area, the 
risk of difficult cannulation is also higher.13 
Hepatopancreatobiliar malignant lesion may 
cause hemostatic disorders, which are associated 
with impaired synthesis of clotting factors in 
the liver. The more difficult the cannulation 
procedure to be performed, the greater the risk 
of biliary trauma and bleeding.13
Subjects with malnutrition had 1.8 times risk 
of death within 6 months following endoscopic 
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biliary stent procedure (95% CI=1.1–2.9) and 
had statistically significant correlation with 
subject survival (p=0.017).
A study by Prat et al7 suggested that the size 
of tumor and weight loss can also be predictors 
of survival. In patients with carcinoma of caput 
pancreas, 80-90% of them will experience a 
significant weight loss at the time the diagnosis 
is made.7 However, the factor is not consistent as 
prognostic factor. Body weight does not exactly 
describe nutritional status of patients with cancer 
since there is extracellular fluid and edema. A 
more meticulous evaluation on nutritional status 
will increase the accuracy of the evaluation as 
in a study conducted by Falconer et al that used 
albumin data.7 It is consistent with the results of 
multivariate analysis of our study, which found 
that malnutrition did not have a strong prognostic 
correlation on subject’s survival with the biggest 
p value (p=0.314) when it was compared to other 
variables.
Albumin is an acute phase protein and its 
level decreases during inflammation, trauma and 
injury. Albumin level can not reflect an adequate 
nutritional intake of the patients. Moreover, 
hypoalbuminemia is highly associated with 
outcomes of mortality and poor morbidities 
such as post-gastrointestinal surgery infection.19 
Based on multivariate analysis in our study, the 
factor that affected subject survival the most 
was low albumin level of ≤ 3.0 g/dL. Subjects 
in such group had 2.73 times greater risk of 
mortality (95%CI: 1.48 – 5.05) compared 
to those in the group with albumin level of 
>3.0 g/dL, and it was statistically significant 
(p=0.001). It is similar to Park et al study20, which 
demonstrated that patients with advanced stage 
of cholangiocarcinoma (unresectable) who had 
albumin level of >3.0 g/dL had better prognosis 
than patients with serum albumin level of ≤ 3.0 g/
dL. Akirov et al21 reported that hypoalbuminemia 
at the time of hospital admission correlated with 
the further lower serum albumin level before 
hospital discharge or on patients’ mortality with 
risk of > 70%. Normalization of albumin level 
before the patients are discharged from the 
hospital is associated with reduced risk of death 
as much as 51%.
The Benefits and Limitations of Study
The present study is the first study 
conducted to evaluate survival following 
palliative endoscopic biliary stent procedure for 
unresectable malignant distal biliary stricture 
cases at Cipto Mangunkusumo Hospital in 
Jakarta. Using cohort design, we could identify 
the proportion, mortality time, median survival 
time and the associated factors. After we evaluate 
the power of survival analysis in this study to 
measure the effect of variables on the survival 
of the subject during 6 months of observation, 
we obtained one variable i.e hypoalbuminemia 
(serum albumin level ≤ 3.0 g/dL) that has 
excellent power (99.6%). The limitation of the 
present study is retrospective design as it was 
based on medical record data; therefore, the 
variables of sepsis, comorbidities and nutritional 
status could not be explored further. Moreover, 
it is difficult to evaluate the non-clinical issues 
that could affect services for the patients such 
as the speed of referral system. Our study was 
conducted only in a single hospital, which is the 
highest referral national hospital in Indonesia; 
therefore, the results may be less representative 
for similar patients in other hospitals of various 
settings.
CONCLUSION
As many as 24% patients with malignant 
distal biliary stricture at Cipto Mangunkusumo 
Hospital survive within a period of 6 months 
following endoscopic biliary stent procedure 
with median survival time of 81 days. Factors 
affecting 6-month survival in patients with 
malignant distal biliary stricture following 
endoscopic biliary stent procedure are albumin 
level of ≤ 3.0 mg/dL with 2.73 times greater 
risk for mortality incidence. The variable has an 
excellent power of study (99.6%).
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